Viridian Therapeutics has historically operated with steep losses driven by heavy R&D and commercial build-out expenditures reflecting its clinical-stage focus. The company’s lead IGF-1R-targeting candidates for thyroid eye disease, veligrotug and elegrobart, are advancing through pivotal phase 3 trials with veligrotug under FDA Priority Review, marking a critical inflection. Efforts to establish commercial operations and market access programs complement its pipeline diversification into FcRn and TSHR inhibitors. Capital raising initiatives including equity offerings and strategic revenue purchase agreements underpin funding runway amid continuing cash burn. Risks remain in regulatory approvals, trial execution, and competitive dynamics as Viridian shifts toward potential product launch readiness.